Purpose: To compare the intraocular pressure (IOP)-lowering efficacy of topically administered bimatoprost 0.03% with la-tanoprost 0.005% in patients with ocular hypertension (OHT) or glaucoma. Design: Multicenter, in...Purpose: To compare the intraocular pressure (IOP)-lowering efficacy of topically administered bimatoprost 0.03% with la-tanoprost 0.005% in patients with ocular hypertension (OHT) or glaucoma. Design: Multicenter, investigator-masked, 6-month randomized clinical trial. Methods: After washout of glaucoma medications, patients with OHT or glaucoma were randomly as-展开更多
Objective: To compare the long-term efficacy and safety of bi-matoprost vs timolol in glaucoma/ocular hypertensive patients. Methods: In a 12-month extension of a multicenter, randomized, double-masked, 1 -year, clini...Objective: To compare the long-term efficacy and safety of bi-matoprost vs timolol in glaucoma/ocular hypertensive patients. Methods: In a 12-month extension of a multicenter, randomized, double-masked, 1 -year, clinical trial, patients were treated with bimatoprost 0.03% QD approximately 8PM (n =167), bimato-prost 0.03% BID (n = 131), or timolol 0.5% BID (n=81). Study visits were scheduled at months 15, 18, 21, and 24 with展开更多
文摘Purpose: To compare the intraocular pressure (IOP)-lowering efficacy of topically administered bimatoprost 0.03% with la-tanoprost 0.005% in patients with ocular hypertension (OHT) or glaucoma. Design: Multicenter, investigator-masked, 6-month randomized clinical trial. Methods: After washout of glaucoma medications, patients with OHT or glaucoma were randomly as-
文摘Objective: To compare the long-term efficacy and safety of bi-matoprost vs timolol in glaucoma/ocular hypertensive patients. Methods: In a 12-month extension of a multicenter, randomized, double-masked, 1 -year, clinical trial, patients were treated with bimatoprost 0.03% QD approximately 8PM (n =167), bimato-prost 0.03% BID (n = 131), or timolol 0.5% BID (n=81). Study visits were scheduled at months 15, 18, 21, and 24 with
